NEW YORK (GenomeWeb) – Cepheid has announced a partnership agreement with Medline for distribution of the GeneXpert platform and menu of 20 approved Xpert tests in the US.

Medline, the largest privately held US healthcare products distributor, will immediately begin offering the platform to non-acute care laboratories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.